CDC - Prostate Cancer

CDC - Prostate Cancer

Prostate Cancer, Genomics & Public Health

CDC information: Prostate cancer-risk factors, symptoms and screening

NCI information: Genetics of prostate cancer (PDQ)

Technology assessment report: Gene expression analysis for prostate cancer management, Blue Cross Blue Shield Health Technology Assessment Report, May 2014

EGAPP recommendation: Does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? (2013)

Prospects for genetic risk screening in prostate cancer, PHG Foundation, Feb 23

Recent papers:

NF-κB gene signature predicts prostate cancer progression. 
Renjie Jin et al. Cancer Research

Prostate Cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. 
Shui IM, et al. Eur Urol. 2014 Jun;65(6):1069-75.

Genetic variants in predicting aggressive prostate cancer: “Ready for prime time?” 
Adriana C. Vidal et al. European Urology: 01 June 2014

Influence of a genomic classifier on postoperative treatment decisions in high-risk prostate cancer patients: Results from the PRO-ACT study 
Michalopoulos SN, et al. Curr Med Res Opin 2014 May

Prostate cancer is the most common cancer among American men. Most prostate cancers grow slowly, and don’t cause any health problems in men who have them.

A prostate specific antigen (PSA) test may find a prostate health problem, but treatment can cause serious side effects. Learn about prostate cancer and talk to your doctor before you decide to get tested or treated for prostate cancer.

Our “Prostate Cancer: Take Time to Decide” infographiclists questions to ask your doctor before you decide to get tested or treated for prostate cancer.More infographics

CDC’s Prostate Cancer Research

• Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
• Patterns of clinical response to PSA elevation in American Indian/Alaska Native men
• Impact of prostate cancer on sexual relationships

More CDC prostate cancer research